1184103-06-7

Upstream product

• 1184103-03-4 methyl 3-(4-chloro-3-hydroxyphenyl)-12-methyl-2-pyridin-4-yl-7,8,9,10-tetrahydro-6H-7,10-epiminocyclohepta-[e]pyrazolo[1,5-a]pyrimidine-8-carboxylate 
• 1134598-81-4 C₁₄H₁₁ClN₄O 
• 13726-21-1 2-(4-chloro-3-methoxyphenyl)acetonitrile 
• 1184103-49-8 3-chloro-2-(4-chloro-3-methoxyphenyl)-3-pyridin-4-ylacrylonitrile 
• 1184103-48-7 2-(4-chloro-3-methoxyphenyl)-3-oxo-3-pyridin-4-ylpropanenitrile 
• 1184103-92-1 8-methyl-2-oxo-8-aza-bicyclo[3.2.1]octane-6-carboxylic acid methyl ester 
• 1134598-81-4 5-(3-amino-5-pyridin-4-yl-1H-pyrazol-4-yl)-2-chlorophenol 
• 1134598-79-0 4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-pyrazol-3-amine 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 

Relevant academic research and scientific papers

Novel pyrazolopyrimidines as highly potent B-Raf inhibitors

A novel series of pyrazolo[1,5-a]pyrimidines bearing a 3-hydroxyphenyl group at C(3) and substituted tropanes at C(7) have been identified as potent B-Raf inhibitors. Exploration of alternative functional groups as a replacement for the C(3) phenol demons

FUSED TRICYCLIC PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Fused, tricyclic pyrazolo{1,5-a]pyrimidine compounds of formula A or of formula B: and pharmaceutically acceptable salts thereof are described, which selectively inhibit Raf kinase activity and are useful for treating disorders mediated by certain Raf kinases.